BayesPrism is a Bayesian deconvolution method that estimates the proportions of different cell types in bulk RNA-seq data while simultaneously inferring gene expression within each of those cell types, using single-cell RNA-seq as prior information.1PubMed Central. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology That dual output, both composition and per-cell-type expression, sets it apart from many deconvolution tools that estimate only one or the other. In independent benchmarks using breast cancer simulations, BayesPrism has shown strong overall accuracy and a particular resistance to the distortions caused by high tumor content, a scenario that trips up several competing methods.
Why Deconvolution of Bulk Data Still Matters
Single-cell sequencing has transformed how researchers study tissues, but it has not made bulk RNA-seq obsolete. Enormous repositories of bulk expression data already exist, describing large patient cohorts with rich clinical annotations, and these archives keep growing because single-cell techniques remain expensive and technically demanding for many labs and tissue types.2Nature Communications. Community assessment of methods to deconvolve cellular composition from bulk gene expression If you could reliably unscramble the cell-type mixture encoded in a bulk sample, you could mine those existing datasets for associations between cellular composition and clinical outcomes without reprocessing every sample at single-cell resolution. That is exactly what deconvolution tools attempt to do, and the number of published methods has grown steadily as the demand for this kind of analysis has increased.
The core challenge is straightforward in principle: a bulk RNA-seq measurement reflects the summed expression of all the cells in a tissue sample. Deconvolution tries to reverse that sum, figuring out what fraction of the sample was, say, T cells versus fibroblasts versus tumor cells, and ideally what those individual populations were expressing. In practice, this is difficult because cell types share many expressed genes, tumor cells are highly variable across patients, and the reference data used to guide deconvolution may not perfectly match the tissue being studied.
How BayesPrism Approaches the Problem
BayesPrism frames deconvolution as a Bayesian inference problem. It takes a single-cell RNA-seq dataset from a similar tissue type as its prior, encoding what each cell type’s expression profile looks like, and then updates those priors with information from the bulk sample to jointly estimate two things: the fraction of each cell type present and the gene expression levels within each cell type for that specific sample.1PubMed Central. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology This joint inference is the method’s defining feature. Rather than first estimating proportions and then trying to back-calculate expression, or vice versa, BayesPrism solves both at once, allowing each estimate to inform the other.
One design decision that matters for cancer research is that BayesPrism explicitly models malignant cells as a heterogeneous category.3bioRxiv. Bayesian cell-type deconvolution and gene expression inference reveals tumor-microenvironment interactions Tumor cells vary enormously from patient to patient, unlike, say, CD8+ T cells, which share a fairly stable transcriptional identity across individuals. Many deconvolution algorithms struggle when a large fraction of the sample consists of a cell type whose expression signature is not well captured by the reference. BayesPrism addresses this by allowing the tumor compartment to be represented by a flexible prior that accounts for patient-specific variation, rather than forcing malignant cells into a single fixed profile.
Benchmark Performance in Breast Cancer Simulations
The most detailed independent head-to-head comparison of deconvolution methods in a cancer context used simulated bulk mixtures derived from breast cancer single-cell data, where the true cell-type proportions were known. This allowed researchers to measure how closely each method’s predictions matched reality across a range of tumor purities, from samples dominated by immune and stromal cells to samples that were almost entirely tumor.
BayesPrism, along with Scaden and MuSiC, consistently outperformed other tested methods across all purity levels, producing the lowest dissimilarity scores between predicted and true proportions. Among those three, the results split by context: Scaden had a slight edge at very low and very high tumor purities, while BayesPrism achieved the best accuracy at all intermediate purity levels.4PubMed Central. Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures The correlation between predicted and true proportions was also high and stable for BayesPrism, with median Pearson’s r values of at least 0.86 across all purity levels.
Where BayesPrism particularly stood out was in robustness. Several other methods, including DWLS, CIBERSORTx (in its CBX mode), Bisque, EPIC, and CPM, performed progressively worse as tumor content increased. Their dissimilarity scores climbed with rising purity, meaning their predictions became less accurate in the very samples where accurate deconvolution matters most: heavily tumor-infiltrated tissues. BayesPrism showed the opposite trend, actually improving as tumor content rose.4PubMed Central. Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures It was the only method that maintained dissimilarity at or below 0.22 across every tested purity level for simulated mixtures from both datasets used in the study.
When the benchmark focused specifically on distinguishing fine-grained immune lineages, BayesPrism and DWLS produced the fewest combined false positives and false negatives.5Nature Communications. Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures Resolving immune cell subtypes is a persistent pain point in deconvolution, because closely related populations like different T cell states or monocyte subtypes share much of their transcriptional identity. The fact that BayesPrism handled this well, even under high tumor content, speaks to the practical value of its Bayesian framework for oncology applications.
What Happens When the Reference Is Missing Cell Types
No single-cell reference is perfect. The atlas you use to guide deconvolution may be missing a cell type that exists in the bulk sample, either because the cell type was lost during tissue dissociation, was rare enough to be filtered out, or simply was not annotated. This is a real-world problem, and it affects BayesPrism along with every other deconvolution approach.
A study that systematically removed cell types from the reference and then measured deconvolution performance found that all tested methods, including BayesPrism, CIBERSORTx, and a simpler non-negative least squares approach, showed degraded accuracy as more cell types were excluded from the reference.6PubMed Central. Missing cell types in single-cell references impact deconvolution of bulk data but are detectable The degradation was especially pronounced when the removed cell types had expression profiles that were relatively distinct from the remaining ones. In those cases, the algorithms tended to redistribute the missing cell type’s signal across whatever remaining types were most similar, inflating their estimated proportions.
The practical takeaway is that reference completeness matters more than which algorithm you choose. If your single-cell reference lacks a major population in the tissue you are deconvolving, all methods will produce distorted estimates. The encouraging finding from the same study is that these gaps are often detectable: residual analysis and goodness-of-fit metrics can flag samples where the model is struggling, which at least tells you something is off even if it cannot tell you exactly what cell type is missing.
Transcriptome Size Bias
A subtler source of error that affects deconvolution broadly, including BayesPrism, involves differences in transcriptome size across cell types. Some cell types naturally produce more total mRNA per cell than others. A large, metabolically active cell like a hepatocyte or a macrophage might have a transcriptome several times larger than that of a resting lymphocyte. When bulk RNA-seq captures total mRNA from a tissue, cell types with larger transcriptomes contribute disproportionately to the signal, not because there are more of them but because each one produces more RNA.
Research has shown that deconvolution methods in general tend to overestimate the proportions of cell types with large transcriptome size while underestimating those with small ones.7Nature Communications. Transcriptome size matters for single-cell RNA-seq normalization and bulk deconvolution This is not a BayesPrism-specific flaw; it reflects a fundamental mismatch between what bulk RNA-seq measures (total mRNA contribution) and what deconvolution tries to estimate (cell counts or cell fractions by number). If you are studying a tissue where cell types have very different per-cell RNA outputs, you should be aware that raw deconvolution proportions may not directly translate into the fraction of cells that are present. Some methods attempt to correct for this, but the correction itself requires assumptions about relative transcriptome sizes that may not be available for every tissue context.
Building the Single-Cell Reference
The quality of what goes in largely determines the quality of what comes out. BayesPrism’s reference is constructed from single-cell RNA-seq data from a tissue type similar to the bulk samples you want to deconvolve. The reference encodes two levels of information: a probability matrix capturing how likely each gene is to be expressed in each cell state, and a mapping layer that groups cell states into broader cell types.8Bioinformatics. InstaPrism: an R package for fast implementation of BayesPrism This two-tier structure, cell states nested within cell types, allows the model to capture finer-grained heterogeneity when it exists while still producing stable cell-type-level estimates.
In practice, building the reference requires raw (non-log-transformed) single-cell expression data along with cell annotations at both the type and state levels. The cell labels are researcher-provided, meaning the quality of upstream clustering and annotation in the single-cell dataset directly shapes the deconvolution results. If the single-cell data were poorly clustered or the annotations conflate two genuinely distinct populations, those errors propagate into every bulk sample you deconvolve. For labs using the R package InstaPrism, a streamlined reimplementation of BayesPrism designed for faster execution, the reference preparation step is handled through a dedicated function that takes these inputs and generates the prior matrix.8Bioinformatics. InstaPrism: an R package for fast implementation of BayesPrism
A common question is whether the single-cell reference needs to come from the same patient cohort as the bulk data. It does not, and in many cases it cannot, since the whole point of deconvolution is to analyze bulk datasets that were collected before single-cell technology was widely available. However, the reference should come from the same tissue context. Using a brain single-cell atlas to deconvolve lung tumor bulk data would produce nonsensical estimates. Even within the same organ, references from a different disease state or developmental stage may introduce biases if the cell type programs have shifted substantially.
Applications in Spatial Transcriptomics
BayesPrism’s usefulness extends beyond traditional bulk RNA-seq. Spatial transcriptomics methods like 10x Visium capture gene expression with spatial coordinates, but each “spot” on the tissue slice still contains a mixture of cells. Researchers have applied BayesPrism to individual spots to estimate cell-type composition at each location, essentially performing deconvolution on hundreds or thousands of tiny bulk mixtures arranged across a tissue section.
In a study of skeletal muscle regeneration, BayesPrism was used to deconvolve spots from both standard Visium data and a newer spatial method called STRS. The resulting cell-type spatial distributions were highly concordant between the two platforms, with mean cell-type fractions across paired samples showing strong agreement.9Nature Biotechnology. Spatial mapping of the total transcriptome by in situ polyadenylation When the researchers merged spots from both methods and performed dimensionality reduction on the deconvolved cell-type fractions, the spots clustered by injury timepoint and tissue region rather than by platform, suggesting that BayesPrism’s estimates were capturing genuine biology rather than technical artifacts. This kind of cross-platform consistency is a useful form of external validation.
Use Cases Beyond Oncology
Although BayesPrism was developed with a focus on tumor-microenvironment interactions, the method itself is not cancer-specific. Any setting where bulk RNA-seq data exist and a reasonable single-cell reference is available can benefit from deconvolution. One example comes from sepsis research, where understanding the immune cell landscape in blood is critical for predicting patient outcomes.
A study integrating single-cell and bulk RNA-seq data from sepsis patients used BayesPrism to deconvolve bulk samples and identify a specific macrophage subtype, FCGR3A+ macrophages, whose associated gene signature had prognostic value. A machine learning model built on genes tied to this macrophage population achieved area-under-the-curve values in the range of 0.69 to 0.77 for predicting 15-day and 21-day mortality across training and validation sets, with one gene, CX3CR1, reaching an individual AUC above 0.98.10Biochemistry and Biophysics Reports. Integration of single-cell and RNA-seq analysis reveals sepsis heterogeneity and prognostic significance of FCGR3A+ Macrophage subtypes The deconvolution step was what allowed the researchers to connect a cell-type-specific signature discovered in single-cell data to clinical outcomes tracked in a much larger bulk cohort. Without that bridge, the single-cell findings would have remained descriptive rather than prognostic.
This kind of cross-platform integration, using single-cell data to generate hypotheses and then validating them in bulk cohorts through deconvolution, is increasingly common in immunology, neuroscience, and developmental biology. BayesPrism’s ability to return per-cell-type expression estimates, not just proportions, makes it particularly suited to workflows where you want to identify differentially expressed genes within a specific cell population across a large number of bulk samples.
Computational Speed and InstaPrism
One practical barrier to BayesPrism’s wider adoption has been runtime. Bayesian inference is computationally heavier than regression-based or matrix-factorization approaches, and running BayesPrism on datasets with thousands of bulk samples can take hours to days depending on the hardware and the size of the reference. This motivated the development of InstaPrism, an R package that reimplements the BayesPrism framework with optimizations aimed at reducing runtime while preserving the same statistical model.8Bioinformatics. InstaPrism: an R package for fast implementation of BayesPrism
For users deciding between the original BayesPrism implementation and InstaPrism, the choice is mostly about scale. If you are deconvolving a handful of samples for a targeted analysis, the original package works fine. If you are processing thousands of TCGA samples or running deconvolution across multiple spatial transcriptomics slides, the speed gains from InstaPrism become meaningful. Both implementations expect the same inputs and produce compatible outputs, so switching between them does not require restructuring your analysis pipeline.
Choosing When to Use BayesPrism
BayesPrism is strongest when you need both cell-type proportions and cell-type-specific expression, when your tissue has high and variable tumor content, or when you care about resolving fine immune lineages. Its benchmark performance in those scenarios is among the best available. It is less clearly dominant when tumor content is negligible, when you only need a rough proportion estimate, or when computational resources are very limited and speed matters more than inference quality.
The method also assumes you have access to a suitable single-cell reference, which is an increasingly reasonable assumption in many tissue contexts but remains a real constraint for understudied organs, rare diseases, or model organisms with sparse single-cell atlases. When no good reference exists, simpler signature-based methods that rely on curated marker gene lists rather than full single-cell profiles may be the more practical option, even if they sacrifice some accuracy.
One scenario where the evidence suggests caution regardless of method is when your tissue contains cell types not represented in the reference or cell types with very different transcriptome sizes. Both of these issues can introduce systematic bias that looks like a biological finding but is actually a technical artifact. Monitoring residuals, running deconvolution with and without suspected problem populations, and cross-checking proportions against orthogonal measurements like immunohistochemistry or flow cytometry are all worth the effort when the stakes of the analysis are high.